[Federal Register Volume 63, Number 138 (Monday, July 20, 1998)]
[Notices]
[Page 38840]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-19145]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institute of Health
Government-Owned Inventions; Availability for Licensing:
Compound, Composition and Method for Treating Cancer
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health is seeking licensees for the
further development, evaluation and commercialization of materials and
methods for a novel cancer treatment strategy. The invention claimed in
DHHS reference No. E-013-96/0, ``Compound, Composition and Method for
Treating Cancer,'' (Hartman, N., et al.) filed on 3 June 1996 as USSN
60/019,086, and in corresponding international filings, is available
for licensing (in accordance with 35 U.S.C. 207 and 37 CFR Part 404).
ADDRESSES: Questions about the licensing opportunity should be
addressed to Girish C. Barua, Ph.D., Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; Telephone: 301/496-7056 ext. 263; Fax:
301/402-0220.
SUPPLEMENTARY INFORMATION: The invention is a novel compound for
treating cancer, Demethylpenclomedine, which is a derivative of the
drug Penclomedine. Penclomedine is already under investigation for its
remarkable preclinical activity against breast cancer, but it suffers
from several dose-limiting side effects. The invention,
Demethylpenclomedine, appears to have reduced toxicity while still
having a similar therapeutic efficacy to that of Penclomedine in animal
models.
Demethylpenclomedine may thus prove to be a useful chemotherapeutic
against breast cancer and other cancers. The lower toxicity may allow
use at higher levels than have been tried with Penclomedine, and other
possible cancers, such as brain tumors, could be targeted.
Information about the patent application and pertinent information
not yet publicly described can be obtained under a Confidential
Disclosure Agreement. Respondees interested in licensing the invention
will be required to submit an Application for License to Public Health
Service Inventions.
Dated: July 6, 1998.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-19145 Filed 7-17-98; 8:45 am]
BILLING CODE 4140-01-M
